Digital Insights to Tumor Biology is a complimentary, half-day virtual event dedicated to embracing not just the power of digital pathology but the value of partnerships and end-to-end workflows to better serve the scientific community. This complimentary digital event will address critical issues around biomarker development.
In this inaugural episode of CLINICAL OMICs Live, sponsored by Fabric Genomics, we welcome Dr. Euan Ashley, a leading medical geneticist at Stanford University, to discuss his new book, The Genome Odyssey. A cardiologist by training, Dr. Ashley has been at the leading edge of genomic medicine for more than a decade. He led the team that conducted arguably the first in-depth interpretation of a full genome sequence. He’s a co-founder of Personalis and other companies.
In this Clinical OMICs webinar, sponsored by Bio-Rad, IncellDx presents an overview of CCR5 antagonists and the ddPCR data that enabled validation of their hypothesis to move 4 CCR5 inhibitors into trials for treatment of COVID-19.
In this Clinical OMICs webinar, sponsored by Illumina, we will discover how combining molecular and immune profiling's power to drive molecular-based testing is improving stratification methods and patient outcomes. Additionally, our expert panelist will showcase the impact of a scalable, comprehensive assay, and infrastructure in the context of drug development.
In this exciting virtual symposium, sponsored by Illumina, we present the latest advances in applications of NGS in the clinical space. The event features a keynote presentation from Dr. Heidi Rehm, followed by plenary talks focusing on three key areas: applications in genetic testing, oncology/cancer diagnostics, and infectious disease detection and testing.
In this exciting new webinar, sponsored by Ultivue, we will explore the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials.
In this Keynote Webinar, sponsored by Illumina, two leading researchers will show how genomic technologies are tackling the COVID-19 pandemic—Alex Greninger, MD, PhD, (University of Washington School of Medicine) and Darrell Dinwiddie PhD, (University of New Mexico Health Sciences Center).
Codevelopment is an intermittent and uncertain process. Adopting an agnostic approach to the challenges associated with platform and method selection provide added degrees of freedom for strategic development and selection of the most appropriate clinical trial assay.
Large cohort studies are essential to the discovery of protein biomarkers, and their validation is indispensable to clinical utility.
The promise of cell and gene therapies to solve some of our most challenging conditions, from rare diseases to cancers, has led this field to remain on the forefront of innovation. Advances in innovative technologies coupled with deeper scientific knowledge in cellular and molecular biology spurred a new era of growth in these advanced therapies.